A novel selection strategy for antibody producing hybridoma cells based on a new transgenic fusion cell line.

Martin Listek, Anja Hönow, Manfred Gossen, Katja Hanack

Scientific reports 2020 Feb 03

filter terms:

The use of monoclonal antibodies is ubiquitous in science and biomedicine but the generation and validation process of antibodies is nevertheless complicated and time-consuming. To address these issues we developed a novel selective technology based on an artificial cell surface construct by which secreted antibodies were connected to the corresponding hybridoma cell when they possess the desired antigen-specificity. Further the system enables the selection of desired isotypes and the screening for potential cross-reactivities in the same context. For the design of the construct we combined the transmembrane domain of the EGF-receptor with a hemagglutinin epitope and a biotin acceptor peptide and performed a transposon-mediated transfection of myeloma cell lines. The stably transfected myeloma cell line was used for the generation of hybridoma cells and an antigen- and isotype-specific screening method was established. The system has been validated for globular protein antigens as well as for haptens and enables a fast and early stage selection and validation of monoclonal antibodies in one step.

Citation

Martin Listek, Anja Hönow, Manfred Gossen, Katja Hanack. A novel selection strategy for antibody producing hybridoma cells based on a new transgenic fusion cell line. Scientific reports. 2020 Feb 03;10(1):1664